The effect of rosiglitazone on retinol binding protein 4 in subjects of impaired glucose tolerance

Chang Hsun Hsieh, Yi Jen Hung, Dee Pei, Chung Ze Wu, Fone Ching Hsiao

Research output: Contribution to journalArticle

Abstract

Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR.

Original languageEnglish
Pages (from-to)250-253
Number of pages4
JournalEndocrinologist
Volume20
Issue number5
DOIs
Publication statusPublished - Oct 2010

Fingerprint

rosiglitazone
Plasma Retinol-Binding Proteins
Retinol-Binding Proteins
Glucose Intolerance
Insulin Resistance
Placebos
Adipokines
Creatine
Aspartate Aminotransferases
Serum
Immunoenzyme Techniques
Triglycerides
Therapeutics
Obesity
Insulin

Keywords

  • impaired glucose tolerance
  • insulin resistance
  • retinol-binding protein-4
  • rosiglitazone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of rosiglitazone on retinol binding protein 4 in subjects of impaired glucose tolerance. / Hsieh, Chang Hsun; Hung, Yi Jen; Pei, Dee; Wu, Chung Ze; Hsiao, Fone Ching.

In: Endocrinologist, Vol. 20, No. 5, 10.2010, p. 250-253.

Research output: Contribution to journalArticle

Hsieh, Chang Hsun ; Hung, Yi Jen ; Pei, Dee ; Wu, Chung Ze ; Hsiao, Fone Ching. / The effect of rosiglitazone on retinol binding protein 4 in subjects of impaired glucose tolerance. In: Endocrinologist. 2010 ; Vol. 20, No. 5. pp. 250-253.
@article{7c5bf4803eea4c89acdb76b5a90c6616,
title = "The effect of rosiglitazone on retinol binding protein 4 in subjects of impaired glucose tolerance",
abstract = "Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR.",
keywords = "impaired glucose tolerance, insulin resistance, retinol-binding protein-4, rosiglitazone",
author = "Hsieh, {Chang Hsun} and Hung, {Yi Jen} and Dee Pei and Wu, {Chung Ze} and Hsiao, {Fone Ching}",
year = "2010",
month = "10",
doi = "10.1097/TEN.0b013e3181f661ec",
language = "English",
volume = "20",
pages = "250--253",
journal = "Endocrinologist",
issn = "1051-2144",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The effect of rosiglitazone on retinol binding protein 4 in subjects of impaired glucose tolerance

AU - Hsieh, Chang Hsun

AU - Hung, Yi Jen

AU - Pei, Dee

AU - Wu, Chung Ze

AU - Hsiao, Fone Ching

PY - 2010/10

Y1 - 2010/10

N2 - Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR.

AB - Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR.

KW - impaired glucose tolerance

KW - insulin resistance

KW - retinol-binding protein-4

KW - rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=77957608372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957608372&partnerID=8YFLogxK

U2 - 10.1097/TEN.0b013e3181f661ec

DO - 10.1097/TEN.0b013e3181f661ec

M3 - Article

AN - SCOPUS:77957608372

VL - 20

SP - 250

EP - 253

JO - Endocrinologist

JF - Endocrinologist

SN - 1051-2144

IS - 5

ER -